Investigators evaluated the efficacy and safety of different doses of MK-2060, a monoclonal antibody against Factor XI, to prevent vascular access clotting in patients receiving hemodialysis via an arteriovenous graft (AVG).
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.
In this episode of AUA Inside Tract, join Dr. Petar Bajic, director of Men’s Health, and Dr. Raevti Bole, Men’s Health specialist, from the Cleveland…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Receive a scholarship grant and execute a year-long research project under the guidance of experts. Finetune your skills and enhance your knowledge in a leading…
June 2025 brings another jam-packed edition of European Urology! Here on the European Urology Podcast we bring you selected highlights from the journal each …
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
The phase 1 study is set to begin later this year.
A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.
